Drug Trial Radar · NCT05624268
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Jan 24, 2023
Primary completion
May 28, 2025
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- COMPASS PathwaysIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Conditions
- Treatment Resistant Depression
Interventions
PsilocybinDrug
COMP360 Psilocybin administered under supportive conditions
Primary outcomes
What the sponsor says the trial is designed to measure.
- COMP360 25 mg versus placebo for the change from baseline in MADRS total scoreTime frame: Week 6
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
University of Arizona College of Medicine - Tuscon
Tuscon, Arizona
ProScience Research Group
Culver City, California
Collaborative Neuroscience Network, LLC
Garden Grove, California
Kadima Neuropsychiatry Institute
La Jolla, California
University California San Diego
La Jolla, California
California Center for Psychedelic Therapy
Los Angeles, California
CalNeuro Research Group, Inc
Los Angeles, California
Clarity Clinical Research, LLC
Los Angeles, California
ATP Clinical Research, Inc.
Orange, California
Artemis Institute for Clinical Research
San Diego, California
Lumos Clinical Research Center
San Jose, California
Stanford University
Stanford, California
ASCLEPES Research Centers
Thousand Oaks, California
Comprehensive Psychiatric Care
Norwich, Connecticut
Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare
Orlando, Florida
APG Research, LLC
Orlando, Florida
DMI Health Care Group, Inc
Tampa, Florida
Meridien Research/Accel Research
Tampa, Florida
Psych Atlanta
Atlanta, Georgia
Emory University
Atlanta, Georgia
Uptown Research Institute, LLC
Chicago, Illinois
Sheppard Pratt Health System
Baltimore, Maryland
CBH Health, LLC
Gaithersburg, Maryland
Pharmasite Research, Inc
Pikesville, Maryland
University of Massachusetts Medical School
North Worcester, Massachusetts
University of Minnesota
Minneapolis, Minnesota
University of Missouri
Columbia, Missouri
Midwest Research Group
Saint Charles, Missouri
Washington University School of Medicine
St Louis, Missouri
Alivation Research, LLC.
Lincoln, Nebraska
Bio Behavioral Health
Toms River, New Jersey
New York State Psychiatric Institute
New York, New York
The Medical Research Network, LLC
New York, New York
Insight Clinical Trials, LLC
Beachwood, Ohio
Neuro-Behaviroral Clinical Research, Inc.
North Canton, Ohio
Rivus Wellness & Research Institute
Oklahoma City, Oklahoma
Global Medical Institutes, LLC, Scranton Medical Institute
Moosic, Pennsylvania
UT Health Science Center at Houston (UTHSC-H)
Houston, Texas
Cedar Clinical Research
Draper, Utah
Core Clinical Research
Everett, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.